TY - JOUR
AU - Taquet, Maxine
AU - Skorniewska, Zuzanna
AU - Zetterberg, Henrik
AU - Geddes, John R.
AU - Mummery, Catherine J.
AU - Chalmers, James D.
AU - Ho, Ling-Pei
AU - Horsley, Alex
AU - Marks, Michael
AU - Poinasamy, Krisnah
AU - Raman, Betty
AU - Leavy, Olivia C.
AU - Richardson, Matthew
AU - Elneima, Omer
AU - McAuley, Hamish
AU - Shikotra, Aarti
AU - Singapuri, Amisha
AU - Sereno, Marco
AU - Saunders, Ruth M.
AU - Harris, Victoria C.
AU - Houchen-Wolloff, Linzy
AU - Mansoori, Parisa
AU - Greening, Neil J.
AU - Harrison, Ewen M.
AU - Docherty, Annemarie B.
AU - Lone, Nazir I.
AU - Quint, Jennifer K.
AU - Greenhalf, William
AU - Wain, Louise V.
AU - Brightling, Christopher E.
AU - Evans, Rachael A.
AU - Harrison, Paul J.
AU - Koychev, Ivan
AU - PHOSP-COVID Study Collaborative Group
PY - 2023
DA - December
TI - Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury
JO - Brain Communications
VL - 6
IS - 1
DO - https://doi.org/10.1093/braincomms/fcad357
AB - A proportion of patients infected with severe acute respiratory syndrome coronavirus 2 experience a range of neuropsychiatric symptoms months after infection, including cognitive deficits, depression and anxiety. The mechanisms underpinning such symptoms remain elusive. Recent research has demonstrated that nervous system injury can occur during COVID-19. Whether ongoing neural injury in the months after COVID-19 accounts for the ongoing or emergent neuropsychiatric symptoms is unclear. Within a large prospective cohort study of adult survivors who were hospitalized for severe acute respiratory syndrome coronavirus 2 infection, we analysed plasma markers of nervous system injury and astrocytic activation, measured 6 months post-infection: neurofilament light, glial fibrillary acidic protein and total tau protein. We assessed whether these markers were associated with the severity of the acute COVID-19 illness and with post-acute neuropsychiatric symptoms (as measured by the Patient Health Questionnaire for depression, the General Anxiety Disorder assessment for anxiety, the Montreal Cognitive Assessment for objective cognitive deficit and the cognitive items of the Patient Symptom Questionnaire for subjective cognitive deficit) at 6 months and 1 year post-hospital discharge from COVID-19. No robust associations were found between markers of nervous system injury and severity of acute COVID-19 (except for an association of small effect size between duration of admission and neurofilament light) nor with post-acute neuropsychiatric symptoms. These results suggest that ongoing neuropsychiatric symptoms are not due to ongoing neural injury.
PB - Oxford University Press
UR - https://discovery.dundee.ac.uk/en/publications/087761e7-bc94-4a85-a6bd-d991872f0c05
KW - Coronavirus (COVID-19)
KW - Mental health and wellbeing
ER